US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products

Commissioner tells House hearing that agency study found troubling drop in innovative competition; clinical trial reform, including encouraging surrogate markers, could speed development of products that may create pricing pressure on brands.